Description: Cancer is often resistant to conventional chemotherapy protocols and therefore has poor clinical outcomes. Beyond chemotherapeutic agents, there are additional non-oncology drugs whose anticancer activity is sporadically reported in the medical literature. In most cases, however, neither patients nor healthcare professionals are aware of the clinically documented therapeutic potential of these remedies. Thus, their compassionate administration is not considered in the treatment of chemoresistant tumors. In layman's terms, the results of a clinical trial are presented, in which an old drug approved for parasitic infections was added to the standard oncology protocol for 24 patients with malignant gliomas. The high-dose oral drug was used in combination with the conventional chemotherapy agent temozolomide. The median survival was 21 months. Glioblastoma patients who receive conventional radiotherapy and chemotherapy survive for about 15 months. At the end of the second year after diagnosis, 41.7% of patients were alive, and 25% were alive at the end of the third and fourth years. The 3-year survival rate for the combination of temozolamide and radiotherapy for gliobastoma is 16%. The only side effect seen was a moderate increase in liver enzymes in some cases. My medical and pharmaceutical background, combined with more than 22 years experience in the daily use of scientific databases, provide a solid basis for the preparation of such report which is supplied in electronic (PDF file) format. References https://scholar.google.com/citations?user=Gqu3u_oAAAAJ&hl=en https://www.scopus.com/authid/detail.uri?authorId=7004151908 https://www.researchgate.net/profile/Ferenc-Zsila
Price: 15 USD
Location: Budakeszi
End Time: 2023-11-23T20:34:48.000Z
Shipping Cost: 0 USD
Product Images
Item Specifics
All returns accepted: ReturnsNotAccepted
